<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00921141</url>
  </required_header>
  <id_info>
    <org_study_id>CCI</org_study_id>
    <secondary_id>CCI</secondary_id>
    <nct_id>NCT00921141</nct_id>
  </id_info>
  <brief_title>Assessment of Complications, Quality of Life and Easiness of Use of Implantable Central Venous Access Ports</brief_title>
  <acronym>CCI</acronym>
  <official_title>Assessment of Complications, Quality of Life and Easiness of Use of Implantable Central Venous Access Ports : Cohort and Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, descriptive and observational study of the anticancer center practice
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and collection of complications for the patients requiring an implantable central venous access ports substitution/change</measure>
    <time_frame>Until the implantable central venous access ports removal</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief description of the different risk factor for morbidity</measure>
    <time_frame>Until the implantable central venous access ports removal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the implantable central venous access ports ease-of-use for nurses according to the modalities of implementation and patient features</measure>
    <time_frame>Until the implantable central venous access ports removal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the patient quality of life</measure>
    <time_frame>Before central venous access ports implementation, at the first day of chemotherapy, and during the cycle 4 of chemotherapy</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">815</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>study population</arm_group_label>
    <description>Patient with cancer requiring a long-term central venous catheter</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All the patients requiring the implementation of a catheter in an anticancerous center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with any cancer, requiring a central venous catheter

          -  No contraindication for any surgery with local or complete anaesthesia

        Exclusion Criteria:

          -  Previous Xylocaine or Lidocaine allergy

          -  Clinic superior vena cava syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice NARDUCCI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2009</study_first_submitted>
  <study_first_submitted_qc>June 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <last_update_submitted>July 20, 2012</last_update_submitted>
  <last_update_submitted_qc>July 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Implantable central venous access ports, cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

